Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies

Hemasphere. 2023 Nov 3;7(11):e975. doi: 10.1097/HS9.0000000000000975. eCollection 2023 Nov.

Authors

Efstathios Kastritis¹, Foteini Theodorakakou¹, Ioannis Ntanasis-Stathopoulos¹, Vassiliki Spiliopoulou¹, Eirini Solia¹, Panagiotis Malandrakis¹, Rodanthi Syrigou¹, Nikoleta Kokkali¹, Magdalini Migkou¹, Evangelos Eleutherakis-Papaiakovou¹, Despina Fotiou¹, Maria Roussou¹, Nikolaos Kanellias¹, Maria Gavriatopoulou¹, Evangelos Terpos¹, Meletios A Dimopoulos¹

Affiliation

¹ Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece.

No abstract available